{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omeprazole+capsule&page=2",
    "query": {
      "intervention": "Omeprazole capsule",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omeprazole+capsule&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T14:14:49.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01059383",
      "title": "Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "VECAM 40/300",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vecta Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 52,
      "start_date": "2009-12",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059383"
    },
    {
      "nct_id": "NCT03059303",
      "title": "Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Simeprevir 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 12.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 75 mg",
          "type": "DRUG"
        },
        {
          "name": "AL-335 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Lansoprazole 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-02-20",
      "completion_date": "2017-04-24",
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03059303"
    },
    {
      "nct_id": "NCT03781596",
      "title": "EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Retrospective evaluation of endoscopy prior to study drug",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Symptom Survey",
          "type": "OTHER"
        },
        {
          "name": "Medication Compliance Phone Call",
          "type": "OTHER"
        },
        {
          "name": "Endoscopy while on study drug",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Claire Daniels",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "6 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-10-02",
      "completion_date": "2022-10-02",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781596"
    },
    {
      "nct_id": "NCT03358706",
      "title": "A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Ustekinumab IV Infusion",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab SC Injection",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Warfarin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Caffeine 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 28,
      "start_date": "2018-02-02",
      "completion_date": "2021-11-22",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 3,
      "location_summary": "Cypress, California • Miami Springs, Florida • Durham, North Carolina",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03358706"
    },
    {
      "nct_id": "NCT04368585",
      "title": "Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)",
          "type": "DRUG"
        },
        {
          "name": "20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spero Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-01",
      "completion_date": "2020-08-21",
      "has_results": false,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368585"
    },
    {
      "nct_id": "NCT03333824",
      "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CYP1A2 (caffeine)",
          "type": "DRUG"
        },
        {
          "name": "CYP2C19 (omeprazole)",
          "type": "DRUG"
        },
        {
          "name": "CYP3A (midazolam)",
          "type": "DRUG"
        },
        {
          "name": "Kytril (granisetron)",
          "type": "DRUG"
        },
        {
          "name": "Wee-1 kinase inhibitor AZD1775",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-12-01",
      "completion_date": "2019-01-22",
      "has_results": false,
      "last_update_posted_date": "2019-03-25",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 7,
      "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03333824"
    },
    {
      "nct_id": "NCT00712413",
      "title": "Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Helicobacter Pylori Infection"
      ],
      "interventions": [
        {
          "name": "OBMT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-08",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712413"
    },
    {
      "nct_id": "NCT00658528",
      "title": "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1061,
      "start_date": "2008-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658528"
    },
    {
      "nct_id": "NCT01129414",
      "title": "Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2009-06",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2011-12-15",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129414"
    },
    {
      "nct_id": "NCT01216293",
      "title": "Effect of Dexlansoprazole on Bone Homeostasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Homeostasis",
        "Bone and Bones"
      ],
      "interventions": [
        {
          "name": "Dexlansoprazole",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "Up to 75 Years · Female only"
      },
      "enrollment_count": 115,
      "start_date": "2010-11-01",
      "completion_date": "2015-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-28T14:14:49.305Z",
      "location_count": 12,
      "location_summary": "San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01216293"
    }
  ]
}